Overcoming chemoresistance in non-small cell lung cancer: Insights into the influence of inflammatory factors on treatment response

Table 1 General information of the patients, n (%)

Variable	Tumor (n = 20)
Sex
Male	11 (55.0)
Female	9 (45.0)
Age (year)	52.75 ± 6.52
TNM stage
Stage I	3 (15.0)
Stage II	5 (25.0)
Stage III	8 (40.0)
Stage IV	4 (20.0)
Histopathological type
Squamous carcinoma	12 (60.0)
Adenocarcinoma	5 (25.0)
Adenosquamous carcinoma	3 (15.0)

Table 2 Univariate logistic regression analysis for the link between inflammatory cytokine levels and cisplatin resistance

Indexes	OR (95%CI)	P value
IL-4	1.603 (0.380-6.773)	0.521
IL-6	1.968 (1.006-3.851)	0.048
IL-8	1.860 (1.014-3.414)	0.045
IL-10	1.833 (0.814-4.128)	0.143
TNF-α	1.437 (0.692-2.988)	0.331

OR: Odds ratio; 95%CI: 95% confidence interval; IL: Interleukin; TNF-α: Tumor necrosis factor-α.